What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The evidence indicates a clear clinical advantage for ibrutinib plus venetoclax over obinutuzumab plus chlorambucil, with significant improvements in progression-free survival and overall survival as demonstrated in the GLOW trial. The hazard ratio of 0.487 indicates a substantial reduction in the risk of progression or death. However, the lack of direct comparisons with other common treatments like acalabrutinib limits the strength of the evidence.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for ibrutinib plus venetoclax are below £20,000 per QALY gained, which is considered acceptable by NICE. The treatment is also noted to be dominant compared to other options, indicating it is both more effective and less costly in certain populations.
Is there quality-of-life evidence payers weigh? — Quality of life
The treatment is associated with a generally acceptable tolerability profile and fewer adverse effects compared to existing therapies, which suggests a moderate improvement in quality of life. However, specific validated HRQoL data were not extensively detailed in the document.
Does the safety profile hold up for payers? — Safety and Adverse Effects
The combination of ibrutinib and venetoclax has an acceptable safety profile, with fewer adverse effects reported compared to traditional therapies. The fixed treatment duration also helps mitigate long-term adverse effects, although some risks like tumor lysis syndrome remain.
Was the drug compared against what payers expect? — Comparator Selection
While the treatment was compared against obinutuzumab plus chlorambucil, there were limitations in the evidence regarding comparisons with other relevant therapies like acalabrutinib and idelalisib plus rituximab, which could affect the robustness of the conclusions drawn.
Is the population defined the way payers need it? — Patient Population and Subgroups
The studies included a representative population of patients with untreated CLL, and the committee noted that the evidence was largely relevant to the intended patient population. However, there were some concerns regarding the heterogeneity of the patient population.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
The treatment can be integrated into existing care pathways with minor adjustments, as it does not require new infrastructure or extensive training, making it a feasible option for clinicians.
Are the wider system costs understood? — Resource Use and Cost Implications
The treatment is expected to have a manageable budget impact, with potential cost savings in certain populations. The economic model suggests that the resource use is justifiable given the benefits provided.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence is supported by high-quality studies, including a Phase 3 trial (GLOW) and a Phase 2 study (CAPTIVATE). However, some limitations exist due to the open-label design and the immaturity of the data.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There are notable uncertainties regarding the long-term treatment effects and the assumptions made in the economic model, particularly concerning the treatment effect waning over time. This uncertainty could impact the overall decision-making process.
